Lineage Cell Therapeutics (LCTX) Times Interest Earned (2010 - 2026)
Lineage Cell Therapeutics (LCTX) posted quarterly Times Interest Earned of -$0.65 for Q1 2026, up 96.97% year-over-year from -$0.33 in Q1 2025, and up 96.95% quarter-over-quarter from -$21.19 in Q4 2025.
Lineage Cell Therapeutics (LCTX) Times Interest Earned (2010 - 2026) Analysis & Trends
Lineage Cell Therapeutics' Times Interest Earned history runs 16 years deep, the most recent figure standing at -$0.65 for Q1 2026.
- In Q1 2026, Times Interest Earned rose 96.97% year-over-year to -$0.65; the TTM figure through Mar 2026 stood at -$3.21 (up 95.52% YoY), while the FY2025 annual figure was -$0.41, down 64.58% from the prior year.
- Times Interest Earned for Q1 2026 stood at -$0.65, up from -$21.19 in the prior quarter.
- The five-year high for Times Interest Earned was $10.05 in Q4 2023, with the low at -$84.68 in Q2 2022.
- The 5-year median for Times Interest Earned is -$11.09 (2023), against an average of -$16.34.
- The sharpest annual moves came in 2023 and 2025: Times Interest Earned soared 148.44% in 2023, then tumbled 698.55% in 2025.
- Lineage Cell Therapeutics' Times Interest Earned stood at -$20.75 in 2022, then jumped by 148.44% to $10.05 in 2023, then plunged by 266.7% to -$16.75 in 2024, then retreated by 26.48% to -$21.19 in 2025, then jumped by 96.95% to -$0.65 in 2026.
- Business Quant data shows LCTX's Times Interest Earned at -$0.65 in Q1 2026, -$21.19 in Q4 2025, and -$0.25 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.84 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 24.64 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -0.19 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.18 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.01 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.61 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.82 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.08 |
| 10 | Lineage Cell Therapeutics | 270.61 Mn | 212.77 Mn | 1.07 Mn | -1.33 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.33 |
| Mar 31, 2026 | -0.65 |
| Dec 31, 2025 | -21.19 |
| Sep 30, 2025 | -0.25 |
| Jun 30, 2025 | -7.18 |
| Mar 31, 2025 | -21.33 |
| Dec 31, 2024 | -16.75 |
| Sep 30, 2024 | -5.26 |
| Jun 30, 2024 | -8.10 |
| Mar 31, 2024 | -2.67 |
| Dec 31, 2023 | 10.05 |
| Sep 30, 2023 | -39.44 |
| Jun 30, 2023 | -11.09 |
| Mar 31, 2023 | -13.07 |
| Dec 31, 2022 | -20.75 |
| Sep 30, 2022 | -10.26 |
| Jun 30, 2022 | -84.68 |
| Mar 31, 2022 | -25.08 |
| Dec 31, 2021 | -113.86 |
| Sep 30, 2021 | -14.88 |